<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32075935</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00204-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00204-20</ELocationID><Abstract><AbstractText>Human enteroviruses (EVs), including coxsackieviruses, the numbered enteroviruses, and echoviruses, cause a wide range of diseases, such as hand, foot, and mouth disease (HFMD), encephalitis, myocarditis, acute flaccid myelitis (AFM), pneumonia, and bronchiolitis. Therefore, broad-spectrum anti-EV drugs are urgently needed to treat EV infection. Here, we demonstrate that FNC (2'-deoxy-2'-&#x3b2;-fluoro-4'-azidocytidine), a small nucleoside analog inhibitor that has been demonstrated to be a potent inhibitor of HIV and entered into a clinical phase II trial in China, potently inhibits the viral replication of a multitude of EVs, including enterovirus 71 (EV71), coxsackievirus A16 (CA16), CA6, EVD68, and coxsackievirus B3 (CVB3), at the nanomolar level. The antiviral mechanism of FNC involves mainly positive- and negative-strand RNA synthesis inhibition by targeting and competitively inhibiting the activity of EV71 viral RNA-dependent RNA polymerase (3D<sup>pol</sup>), as demonstrated through quantitative real-time reverse transcription-PCR (RT-qPCR), <i>in vitro</i> 3D<sup>pol</sup> activity, and isothermal titration calorimetry (ITC) experiments. We further demonstrated that FNC treatment every 2 days with 1&#x2009;mg/kg of body weight in EV71 and CA16 infection neonatal mouse models successfully protected mice from lethal challenge with EV71 and CA16 viruses and reduced the viral load in various tissues. These findings provide important information for the clinical development of FNC as a broad-spectrum inhibitor of human EV pathogens.<b>IMPORTANCE</b> Human enterovirus (EV) pathogens cause various contagious diseases such as hand, foot, and mouth disease, encephalitis, myocarditis, acute flaccid myelitis, pneumonia, and bronchiolitis, which have become serious health threats. However, except for the EV71 vaccine on the market, there are no effective strategies to prevent and treat other EV pathogen infections. Therefore, broad-spectrum anti-EV drugs are urgently needed. In this study, we demonstrated that FNC, a small nucleoside analog inhibitor that has been demonstrated to be a potent inhibitor of HIV and entered into a clinical phase II trial in China, potently inhibits the viral replication of a multitude of EVs at the nanomolar level. Further investigation revealed that FNC inhibits positive- and negative-strand RNA synthesis of EVs by interacting and interfering with the activity of EV71 viral RNA-dependent RNA polymerase (3D<sup>pol</sup>). Our findings demonstrate for the first time that FNC is an effective broad-spectrum inhibitor for human EV pathogens.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Xu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Institute of Radiation Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Baisong</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Institute of Radiation Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huan</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shengqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing Institute of Radiation Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Junbiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China changjunbiao@zzu.edu.cn zhangwenyan@jlu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China changjunbiao@zzu.edu.cn zhangwenyan@jlu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001386">Azides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>IJ2XP0ID0K</RegistryNumber><NameOfSubstance UI="C540945">azvudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K8CXK5Q32L</RegistryNumber><NameOfSubstance UI="C030986">pyrimidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001386" MajorTopicYN="N">Azides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FNC</Keyword><Keyword MajorTopicYN="N">enteroviruses</Keyword><Keyword MajorTopicYN="N">inhibition</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">viral RNA polymerase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32075935</ArticleId><ArticleId IdType="pmc">PMC7163137</ArticleId><ArticleId IdType="doi">10.1128/JVI.00204-20</ArticleId><ArticleId IdType="pii">JVI.00204-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abzug MJ. 2014. The enteroviruses: problems in need of treatments. J Infect 68(Suppl 1):S108&#x2013;S114. doi:10.1016/j.jinf.2013.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2013.09.020</ArticleId><ArticleId IdType="pubmed">24119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating J, van Kuppeveld F. 2018. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol 16:368&#x2013;381. doi:10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanter M, Sork H, Tuomela S, Flodstrom-Tullberg M. 2019. Genetic and environmental interaction in type 1 diabetes: a relationship between genetic risk alleles and molecular traits of enterovirus infection? Curr Diab Rep 19:82. doi:10.1007/s11892-019-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-019-1192-8</ArticleId><ArticleId IdType="pmc">PMC6689284</ArticleId><ArticleId IdType="pubmed">31401790</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra AM, Waseem M. 2019. Hand foot and mouth disease. StatPearls Publishing LLC, Treasure Island, FL.</Citation><ArticleIdList><ArticleId IdType="pubmed">28613736</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Hu XY, Yu XF. 2019. Current understanding of human enterovirus D68. Viruses 11:490. doi:10.3390/v11060490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P-C, Chen S-C, Chen K-T. 2016. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health 13:890. doi:10.3390/ijerph13090890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Luo Z, Wang J, Xu Z, Chen H, Fan D, Gao N, Ping G, Zhou Z, Zhang Y, An J. 2013. Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PLoS One 8:e56318. doi:10.1371/journal.pone.0056318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056318</ArticleId><ArticleId IdType="pmc">PMC3572022</ArticleId><ArticleId IdType="pubmed">23418551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, Earl P, Bendig J, Tong CY. 2008. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 46:3192&#x2013;3200. doi:10.1128/JCM.00628-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00628-08</ArticleId><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Gonfrier G, Ninove L, Zandotti C, Dubot-Peres A, de Lamballerie X, Charrel RN. 2012. Screening and detection of human enterovirus 71 infection by a real-time RT-PCR assay in Marseille, France, 2009&#x2013;2011. Clin Microbiol Infect 18:E77&#x2013;E80. doi:10.1111/j.1469-0691.2012.03769.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03769.x</ArticleId><ArticleId IdType="pubmed">22332991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda C, Singh R, Rana SK. 2015. An outbreak of hand-foot-mouth disease: a report from the hills of northern India. Natl Med J India 28:126&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">26724340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Jiang DS, Wu HM, Chen HH. 2016. A dynamic model for the outbreaks of hand, foot, and mouth disease in Taiwan. Epidemiol Infect 144:1500&#x2013;1511. doi:10.1017/S0950268815002630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815002630</ArticleId><ArticleId IdType="pmc">PMC4823833</ArticleId><ArticleId IdType="pubmed">26567705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Goggins WB, Chan EY. 2016. Hand, foot and mouth disease in Hong Kong: a time-series analysis on its relationship with weather. PLoS One 11:e0161006. doi:10.1371/journal.pone.0161006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161006</ArticleId><ArticleId IdType="pmc">PMC4988669</ArticleId><ArticleId IdType="pubmed">27532865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Wang Y, Yao X, Mao Q, Xu M, Liang Z. 2015. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther 13:1061&#x2013;1071. doi:10.1586/14787210.2015.1058156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2015.1058156</ArticleId><ArticleId IdType="pubmed">26112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CT, Jiang L, Ma S, James L, Ang LW. 2016. Basic reproduction number of coxsackievirus type A6 and A16 and enterovirus 71: estimates from outbreaks of hand, foot and mouth disease in Singapore, a tropical city-state. Epidemiol Infect 144:1028&#x2013;1034. doi:10.1017/S0950268815002137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815002137</ArticleId><ArticleId IdType="pubmed">26374168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H, Zhang Y, Sun Q, Zhu S, Li X, Pan Z, Xu W, Xu B. 2014. Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei Province, China: outbreaks of coxsackieviruses A10 and B3. PLoS One 9:e84233. doi:10.1371/journal.pone.0084233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084233</ArticleId><ArticleId IdType="pmc">PMC3879295</ArticleId><ArticleId IdType="pubmed">24392117</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ding J, Cao J, Huang Q, Hong C, Yang B. 2015. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol 87:954&#x2013;960. doi:10.1002/jmv.24151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao J, Qin Z, Zuo Z, Yu S, Zhang J. 2016. Spatial-temporal mapping of hand foot and mouth disease and the long-term effects associated with climate and socio-economic variables in Sichuan Province, China from 2009 to 2013. Sci Total Environ 563&#x2013;564:152&#x2013;159. doi:10.1016/j.scitotenv.2016.03.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2016.03.159</ArticleId><ArticleId IdType="pubmed">27135578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang FC, Yang F, Chen L, Jia J, Han YL, Hao B, Cao GW. 2016. Meteorological factors affect the hand, foot, and mouth disease epidemic in Qingdao, China, 2007&#x2013;2014. Epidemiol Infect 144:2354&#x2013;2362. doi:10.1017/S0950268816000601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816000601</ArticleId><ArticleId IdType="pmc">PMC9150528</ArticleId><ArticleId IdType="pubmed">27018924</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK. 2016. Global emergence of enterovirus D68: a systematic review. Lancet Infect Dis 16:e64&#x2013;e75. doi:10.1016/S1473-3099(15)00543-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00543-5</ArticleId><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfferich J, Knoester M, Van Leer-Buter CC, Neuteboom RF, Meiners LC, Niesters HG, Brouwer OF. 2019. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr 178:1305&#x2013;1315. doi:10.1007/s00431-019-03435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-019-03435-3</ArticleId><ArticleId IdType="pmc">PMC6694036</ArticleId><ArticleId IdType="pubmed">31338675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ. 2010. Developments towards antiviral therapies against enterovirus 71. Drug Discov Today 15:1041&#x2013;1051. doi:10.1016/j.drudis.2010.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Benschop KS, van der Avoort HG, Duizer E, Koopmans MP. 2015. Antivirals against enteroviruses: a critical review from a public-health perspective. Antivir Ther 20:121&#x2013;130. doi:10.3851/IMP2939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP2939</ArticleId><ArticleId IdType="pubmed">25643052</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S, Andino R. 2002. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 4:1301&#x2013;1307. doi:10.1016/s1286-4579(02)00008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1286-4579(02)00008-4</ArticleId><ArticleId IdType="pubmed">12443894</ArticleId></ArticleIdList></Reference><Reference><Citation>de L&#xe9;dinghen V, Trimoulet P, Winnock M, Foucher J, Bourliere M, Desmorat H, Canva V, Capron D, Levy S, Mion F, Mannant PR, Chene G, Fleury H, Couzigou P, Bernard PH. 2002. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol 36:672&#x2013;680. doi:10.1016/S0168-8278(02)00026-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(02)00026-0</ArticleId><ArticleId IdType="pubmed">11983451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyde PR. 1998. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 39:63&#x2013;79. doi:10.1016/s0166-3542(98)00029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-3542(98)00029-1</ArticleId><ArticleId IdType="pubmed">9806484</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, Yu CK, Chen SH. 2008. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 197:854&#x2013;857. doi:10.1086/527326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/527326</ArticleId><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR. 2009. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother 53:2740&#x2013;2747. doi:10.1128/AAC.00101-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, Hsu JT, Tseng CP. 2010. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother 65:676&#x2013;683. doi:10.1093/jac/dkp502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkp502</ArticleId><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="pubmed">20089540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X, Qiu M, Chen D, Zheng N, Jin Y, Wu Z. 2014. Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. Antiviral Res 109:30&#x2013;41. doi:10.1016/j.antiviral.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.06.004</ArticleId><ArticleId IdType="pubmed">24971492</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Li S, Du L, Chen S, Gao J, Cai Y, Xu Z, Zhao Z, Lan K, Wu S. 2020. Emetine protects mice from enterovirus infection by inhibiting viral translation. Antiviral Res 173:104650. doi:10.1016/j.antiviral.2019.104650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104650</ArticleId><ArticleId IdType="pubmed">31734270</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De Witte A, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB. 2008. 2&#x2032;-Deoxy-4&#x2032;-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2&#x2032;-alpha-hydroxyl groups. J Biol Chem 283:2167&#x2013;2175. doi:10.1074/jbc.M708929200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M708929200</ArticleId><ArticleId IdType="pubmed">18003608</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DB, Kalayanov G, Sund C, Winqvist A, Maltseva T, Leveque VJ, Rajyaguru S, Le Pogam S, Najera I, Benkestock K, Zhou XX, Kaiser AC, Maag H, Cammack N, Martin JA, Swallow S, Johansson NG, Klumpp K, Smith M. 2009. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4&#x2032;-azidocytidine against hepatitis C virus replication: the discovery of 4&#x2032;-azido-2&#x2032;-deoxy-2&#x2032;-fluorocytidine and 4&#x2032;-azido-2&#x2032;-dideoxy-2&#x2032;,2&#x2032;-difluorocytidine. J Med Chem 52:2971&#x2013;2978. doi:10.1021/jm801595c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm801595c</ArticleId><ArticleId IdType="pubmed">19341305</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Wang Q, Yang X, Guo X, Chen L, Tao L, Dong L, Li Y, An H, Yu X, Wang Q, Chang J. 2012. Antiviral activity of FNC, 2&#x2032;-deoxy-2&#x2032;-beta-fluoro-4&#x2032;-azidocytidine, against human and duck HBV replication. Antivir Ther 17:679&#x2013;687. doi:10.3851/IMP2094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP2094</ArticleId><ArticleId IdType="pubmed">22452880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang Y, Yang X, Zhao J, Zheng L, Sun C, Jiang J, Yang Q, Wang Q, Chang J. 2012. Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates. Antivir Ther 17:1593&#x2013;1599. doi:10.3851/IMP2292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP2292</ArticleId><ArticleId IdType="pubmed">22910281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang X, Gao C, Song X, Niu Z, Gao Z, Qin Z, Chang J, Wang H. 2013. The pyrimidine analog FNC inhibits cell proliferation and viral protein synthesis in HTLV1infected cells. Mol Med Rep 7:1656&#x2013;1660. doi:10.3892/mmr.2013.1358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2013.1358</ArticleId><ArticleId IdType="pubmed">23467991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Liu X, Wang Q, Zhang Y, Jiang J, Guo X, Fan Q, Zheng L, Yu X, Wang N, Pan Z, Song C, Qi W, Chang J. 2011. FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells. Biochem Pharmacol 81:848&#x2013;855. doi:10.1016/j.bcp.2011.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.01.001</ArticleId><ArticleId IdType="pubmed">21219886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang RR, Yang QH, Luo RH, Peng YM, Dai SX, Zhang XJ, Chen H, Cui XQ, Liu YJ, Huang JF, Chang JB, Zheng YT. 2014. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One 9:e105617. doi:10.1371/journal.pone.0105617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105617</ArticleId><ArticleId IdType="pmc">PMC4140803</ArticleId><ArticleId IdType="pubmed">25144636</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu B, Zhang Y, Peng Y, Huang C, Wang N, Jiang J, Wang Q, Chang J. 2017. Intestinal absorption mechanisms of 2&#x2032;-deoxy-2&#x2032;-beta-fluoro-4&#x2032;-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein. Eur J Pharm Sci 105:150&#x2013;158. doi:10.1016/j.ejps.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.05.009</ArticleId><ArticleId IdType="pubmed">28487144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R. 2000. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 7:167&#x2013;174. doi:10.1046/j.1365-2893.2000.00218.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2893.2000.00218.x</ArticleId><ArticleId IdType="pubmed">10849258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J, Li J, Liu X, Liu G, Yang J, Wei W, Zhang W, Yu X-F. 2015. Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice. BMC Microbiol 15:139&#x2013;139. doi:10.1186/s12866-015-0474-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-015-0474-9</ArticleId><ArticleId IdType="pmc">PMC4501189</ArticleId><ArticleId IdType="pubmed">26169371</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Chang J, Liu X, Yang J, Guo H, Wei W, Zhang W, Yu X-F. 2014. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol 95:1083&#x2013;1093. doi:10.1099/vir.0.063560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.063560-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Ning S, Su X, Liu X, Wang H, Liu Y, Zheng W, Zheng B, Yu XF, Zhang W. 2018. Enterovirus 71 antagonizes the inhibition of the host intrinsic antiviral factor A3G. Nucleic Acids Res 46:11514&#x2013;11527. doi:10.1093/nar/gky840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky840</ArticleId><ArticleId IdType="pmc">PMC6265463</ArticleId><ArticleId IdType="pubmed">30247716</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumpp K, L&#xe9;v&#xea;que V, Le Pogam S, Ma H, Jiang W-R, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, N&#xe1;jera I. 2006. The novel nucleoside analog R1479 (4&#x2032;-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 281:3793&#x2013;3799. doi:10.1074/jbc.M510195200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M510195200</ArticleId><ArticleId IdType="pubmed">16316989</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. 2007. Design, synthesis, and antiviral properties of 4&#x2032;-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett 17:2570&#x2013;2576. doi:10.1016/j.bmcl.2007.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2007.02.004</ArticleId><ArticleId IdType="pubmed">17317178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhu C, Bao W, Zhao K, Niu J, Yu XF, Zhang W. 2012. Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One 7:e32405. doi:10.1371/journal.pone.0032405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032405</ArticleId><ArticleId IdType="pmc">PMC3315555</ArticleId><ArticleId IdType="pubmed">22479324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Guo H, Li J, Ren S, Wei Z, Bao W, Hu X, Zhao K, Zhang W, Zhou Y, Sun F, Markham R, Yu XF. 2014. Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS One 9:e94746. doi:10.1371/journal.pone.0094746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094746</ArticleId><ArticleId IdType="pmc">PMC3988102</ArticleId><ArticleId IdType="pubmed">24736564</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, van Boom JH, Filippov D, Wimmer E. 1998. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393:280&#x2013;284. doi:10.1038/30529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/30529</ArticleId><ArticleId IdType="pubmed">9607767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma-Wong MF, Dewalt PG, Johnson VH, Lamb JG, Semler BL. 1988. Protein 3CD is the major poliovirus proteinase responsible for cleavage of the P1 capsid precursor. Virology 166:265&#x2013;270. doi:10.1016/0042-6822(88)90172-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(88)90172-9</ArticleId><ArticleId IdType="pubmed">2842953</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, Harris KS, Alexander L, Wimmer E. 1995. Interaction between the 5&#x2032;-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J Virol 69:3658&#x2013;3667. doi:10.1128/JVI.69.6.3658-3667.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.6.3658-3667.1995</ArticleId><ArticleId IdType="pmc">PMC189081</ArticleId><ArticleId IdType="pubmed">7745714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Su J, Wang H, Chang J, Wang S, Zheng W, Cai Y, Wei W, Gordy JT, Markham R, Kong W, Zhang W, Yu XF. 2017. Disruption of MDA5-mediated innate immune responses by the 3C proteins of coxsackievirus A16, coxsackievirus A6, and enterovirus D68. J Virol 91:e00546-17. doi:10.1128/JVI.00546-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00546-17</ArticleId><ArticleId IdType="pmc">PMC5469270</ArticleId><ArticleId IdType="pubmed">28424289</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-&#xc1;lvarez Y, Arias A, Del &#xc1;guila C, Agudo R. 2019. Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs. Sci Rep 9:5397&#x2013;5397. doi:10.1038/s41598-019-41998-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41998-1</ArticleId><ArticleId IdType="pmc">PMC6444013</ArticleId><ArticleId IdType="pubmed">30932009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>